J Gastroenterol: Multi-target small molecule tyrosine kinase inhibitor Cabotinib is effective in treating advanced liver cancer

Cabozantinib is a small multi-target molecule tyrosine kinase inhibitor with 9 targets: MET, VEGFR1, VEGFR 2, VEGFR 3, ROS1, RET, AXL, NTRK, KIT.
This study is an open one-arm Phase 2 trial that recruits patients with advanced hepatocellular carcinoma (HCC) who have previously received advances after treatment with one or both systems, including sorabinib, to assess the efficacy and safety of capotinib in such patients.
also conducted exploratory assessments in patients who had not been treated with sorafine.
study program were treated with oral capodinib 60 mg per day.
end point is the progress-free survival rate (PFS) for week 24.
secondary endpoints include PFS, Total Lifetime (OS), Objective Mitigation Rate (ORR, Full/Partial Mitigation Best Response), Disease Control Rate (DCR, Objective Mitigation or Disease Stability), and Safety.
PFS34 patients from two cohort patients received cabotinib treatment at 17 centres (Sorafini queue n=20; Sorafininib untreated queue, n=14).
24 weeks, the PFS rate of the Sorafini group was 59.8% (90% CI 36.1-77.2%), while that of the Sorafinie group was 16.7% (4.0-36.8%), and the overall PFS rate was 40.1% (24.8-55.0%).
median PFS for the Sorafinie queue was 7.4 months, and the median for the Sorafinie queue was 3.6 months, for a total of 5.6 months.
six-month OS rates were 100.0%, 78.6% and 91.1%, respectively, and DCR was 85.0%, 64.3% and 76.5%, respectively.
ORR for both queues is 0.0%.
adverse reactions all patients need to adjust the dose due to adverse events, the most common of which are palm erythema disorder syndrome and diarrhea.
3 patients (8.8%) were deactived with capodinib due to adverse events other than disease progression.
addition, Cabotinib 60 mg/day has good therapeutic benefits and manageable risks for patients with advanced HCC who have received one or two systemic anti-cancer treatments, including soraphinib.
。